To evaluate the suitability of FGL2 as a target for T cell therapy with low risk of off-tumor on-target toxicity, we assessed the expression of FGL2 in human GBM and normal tissue arrays using FGL2 mAb-clone #4, from which the αFGL2 construct was derived. Here, FGL2 is linked to neoplasm.